BioStock: Saniona ready to advance its Kv7 programme

Saniona has announced that the company is on the cusp of advancing its Kv7 programme for epilepsy to lead optimisation, which is the final phase of drug discovery before a clinical candidate is selected. BioStock reached out to CEO Thomas Feldthus to learn more about this new programme.

Read the interview with Saniona's CEO Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2022/08/saniona-ready-to-advance-its-kv7-programme/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/